CytoSorbents Corporation (CTSO)

[orangecat]

Cytosorbents, as Dr. Chan and Ms. Bloch have said a number of times, has been "de-risked". The product works, there is demand for the product, an earlier adopter hospital purchasing over 1 million in Cytosorb in a year is evidence of this, infrastructure is in place to expand production, many patents in place to secure the rights to the technology, multiple strategic partners on board to expand sales territory and a product pipeline for future expansion with Hemodefend, Cytosorb XL, Potassium absorber, Contrasorb, etc.